Association between atopic dermatitis and attention deficit hyperactivity disorder in U.S. children and adults

Strom, Mark A.; Fishbein, Anna; Paller, Amy S.; Silverberg, Jonathan I.

doi:10.1111/bjd.14697

Cited by 165 publications

(144 citation statements)

References 47 publications

Supporting

Mentioning

129

Contrasting

Unclassified

Order By: Relevance

“…For many, severe chronic itch impacts sleep and productivity . Mental health disorders, including anxiety, depression and attention‐deficit/hyperactivity disorder, are also more common in both children and adults with AD . In addition, altered immune responses render patients with AD at increased risk of bacterial, viral and fungal skin infections, particularly by Staphylococcus aureus and herpes simplex type 1 virus …”

Section: Introductionmentioning

confidence: 99%

Understanding the immune landscape in atopic dermatitis: The era of biologics and emerging therapeutic approaches

Moyle¹,

Cevikbas

Harden

et al. 2019

Experimental Dermatology

132

148

View full text Add to dashboard Cite

Atopic dermatitis (AD) is a chronic, systemic, inflammatory disease that affects the skin and is characterized by persistent itch and marked redness. AD is associated with an increased risk of skin infections and a reduced quality of life. Most AD treatment options to date were not designed to selectively target disease‐causing pathways that have been established for this indication. Topical therapies have limited efficacy in moderate‐to‐severe disease, and systemic agents such as corticosteroids and immunosuppressants present with tolerability issues. Advances in the understanding of AD pathobiology have made possible a new generation of more disease‐specific AD therapies. AD is characterized by the inappropriate activation of type 2 T helper (Th2) cells and type 2 innate lymphoid (ILC2) cells, with a predominant increase in type 2 cytokines in the skin, including interleukin (IL)‐13 and IL‐4. Both cytokines are implicated in tissue inflammation and epidermal barrier dysfunction, and monoclonal antibodies targeting each of these interleukins or their receptors are in clinical development in AD. In March 2017, dupilumab, a human anti–IL‐4Rα antibody, became the first biologic to receive approval in the United States for the treatment of moderate‐to‐severe AD. The anti–IL‐13 monoclonal antibodies lebrikizumab and tralokinumab, which bind different IL‐13 epitopes with potentially different effects, are currently in advanced‐stage trials. Here, we briefly review the underlying pathobiology of AD, the scientific basis for current AD targets, and summarize current clinical studies of these agents, including new research to develop both predictive and response biomarkers to further advance AD therapy in the era of precision medicine.

show abstract

Section: Introductionmentioning

confidence: 99%

Understanding the immune landscape in atopic dermatitis: The era of biologics and emerging therapeutic approaches

Moyle¹,

Cevikbas

Harden

et al. 2019

Experimental Dermatology

132

148

View full text Add to dashboard Cite

show abstract

“…1,5,6 Severe pruritus induces sleep disturbance in AD patients and their caregivers. [7][8][9] The itch-sleepless circuit may increase attentiondeficit/hyperactivity disorder in children as well as in adults with AD. 8,9 Their stress levels are also very high.…”

Section: Introductionmentioning

confidence: 99%

“…[7][8][9] The itch-sleepless circuit may increase attentiondeficit/hyperactivity disorder in children as well as in adults with AD. 8,9 Their stress levels are also very high. 10 Atopic dermatitis is more frequent in childhood, especially in the first five years of life.…”

Section: Introductionmentioning

confidence: 99%

T helper type 2 signatures in atopic dermatitis

Furue

2018

J Cutaneous Imm & Allergy

View full text Add to dashboard Cite

“…There are emerging data suggesting a higher incidence of ADHD in children with atopic disease(Strom, Fishbein, Paller, & Silverberg, 2016).The children's single-item household literacy query correlated positively with the parents NVS score (r s = 0.688, p = 0.001). There was also a negative association between children being treated for ADHD and their satisfaction with school (r s = −0.451, p = 0.046) and living environment (r s = −0.562, p = 0.010).…”

mentioning

confidence: 98%

Life satisfaction in children with attention deficit hyperactivity disorder: Looking beyond proxy reports

Barfield

2018

Child Adoles Psych Nursing

View full text Add to dashboard Cite

Problem A common clinical approach to children with attention deficit hyperactivity disorder (ADHD) is to view them through an adult‐proxy report of problems. There is little evidence on how children with ADHD evaluate their life satisfaction, how their evaluations compare with unaffected children, or how their perspectives might inform clinical practice. Methods A parallel convergent mixed‐methods design was used to interview 20 children (aged, 7–11 years) with ADHD. This report presents the children's responses to the 40‐item Multidimensional Student Life Satisfaction Scale. Parents/guardians ( N = 20) provided contextual data consisting of demographics, ADHD‐related items, and health literacy. Findings Total life satisfaction (M = 3.08, SD = 0.35) fell within the 95% CI [2.91, 3.25] of comparative data. Overall subscale ratings (high to low) included: friends (M = 3.24, SD = 0.60), living environment (M = 3.14, SD = 0.51), family (M = 3.08, SD = 0.51), school (M = 3.0, SD = 0.65), and self (M = 2.93, SD = 0.60). Positive and negative associations are reported. Conclusions Including a measure of life satisfaction adds a child‐centered approach to understanding children with ADHD beyond an adult‐proxy report of problems that is contextually and clinically relevant.

show abstract

Association between atopic dermatitis and attention deficit hyperactivity disorder in U.S. children and adults

Abstract: Atopic dermatitis is associated with increased odds of ADD/ADHD in adults and children. Several factors increase the risk of ADHD in adults and children with AD.

Cited by 165 publications

References 47 publications

Understanding the immune landscape in atopic dermatitis: The era of biologics and emerging therapeutic approaches

Understanding the immune landscape in atopic dermatitis: The era of biologics and emerging therapeutic approaches

T helper type 2 signatures in atopic dermatitis

Life satisfaction in children with attention deficit hyperactivity disorder: Looking beyond proxy reports

Contact Info

Product

Resources

About